Skip to content
2000
Volume 25, Issue 4
  • ISSN: 1871-5265
  • E-ISSN: 2212-3989

Abstract

This review explores various biliary tract diseases caused by different organisms, including cholelithiasis, hepatolithiasis, and choledocholithiasis. The biliary tract's primary functions include collecting, storing, concentrating, and delivering bile juice produced by the liver. Neurohormonal systems involving the vagus and splanchnic nerves, alongside cholecystokinin, regulate gallbladder movement during fasting and digestion. Under normal conditions, bile acids play a crucial role, with approximately 95% being reabsorbed by the intestinal epithelium and returned to the liver the portal vein system. The liver, often hailed as a miracle worker, detoxifies, purifies, and regenerates, performi ng essential functions in the body. Recent research indicates that the gallbladder, akin to the intestine, harbors a diverse microbiota. Additionally, the biliary mucosa features chemical, mechanical, and immunological barriers that promote immunological tolerance. Hepatotoxicity remains a significant global health concern and a leading cause of mortality. Providing clear and accurate information on liver toxicity is critical, especially in the context of medication safety and public health. By refining these elements, this review can effectively convey the complexity and importance of biliary tract diseases and liver function in health and disease contexts.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/iddt/10.2174/0118715265302000240913092037
2024-10-29
2025-10-28

  • From This Site

    /content/journals/iddt/10.2174/0118715265302000240913092037
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. BeharJ. Physiology and pathophysiology of the biliary tract: the gallbladder and sphincter of Oddi-a review.ISRN Physiol.2013201383763010.1155/2013/837630
     [Google Scholar]
  2. PradhanS.B. DaliS. Relation between gallbladder neoplasm and Helicobacter hepaticus infection.Kathmandu Univ. Med. J.200424331335 16388245
     [Google Scholar]
  3. GBD Mortality and causes of death, collaborators. Global regional and national age sex specific all cause and cause specific mortality for 240 causes of death, 1990-2013: a systemic analysis for the global burden of disease study.Lancet20133859963117171
     [Google Scholar]
  4. ScottA.J. Bacteria and disease of the biliary tract.Gut197112648749210.1136/gut.12.6.487 4933136
     [Google Scholar]
  5. PandeyM. Helicobacter species are associated with possible increase in risk of biliary lithiasis and benign biliary diseases.World J. Surg. Oncol.2007519410.1186/1477‑7819‑5‑94 17708763
     [Google Scholar]
  6. NeriV. MargiottaM. De FrancescoV. DNA sequences and proteic antigens of H. pylori in cholecystic bile and tissue of patients with gallstones.Aliment. Pharmacol. Ther.200522871572010.1111/j.1365‑2036.2005.02644.x 16197492
     [Google Scholar]
  7. ElkelesG. MirizziP.L. A study of the bacteriology of the common bile duct in comparison with the other extrahepatic segments of the biliary tract.Ann. Surg.1942116336036610.1097/00000658‑194209000‑00007 17858101
     [Google Scholar]
  8. EdlundY.A. MollstedtB.O. OuchterlonyO. Bacteriological investigation of the biliary system and liver in biliary tract disease correlated to clinical data and microstructure of the gallbladder and liver.Acta Chir. Scand.19591165-6461476 13660715
     [Google Scholar]
  9. GlennF. WantzG.E. Acute cholecystitis following the surgical treatment of unrelated disease.Surg. Gynecol. Obstet.19561022145153 13299028
     [Google Scholar]
  10. McFadyeanF. StockmanS. Report of the Department Committee appointed by the Board of Agriculture and Fisheries to inquire into epizootic abortion.LondonHis Majesty’s Stationary Office1909
     [Google Scholar]
  11. VinzentR. DumasJ. PicardN. Septicemie grave au cours de la grossesse due a un vibrion: avortiment consecutif.Bull. Acad Natl. Med.19471319093
     [Google Scholar]
  12. FoxJ.G. DewhirstF.E. ShenZ. Hepatic Helicobacter species identified in bile and gallbladder tissue from chileans with chronic cholecystitis.Gastroenterology1998114475576310.1016/S0016‑5085(98)70589‑X 9516396
     [Google Scholar]
  13. MamathaB. ShenoyP.A. Sunil RodriguesG. Biliary tract infections and their Microbiological Spectrum- A study from coastal region of Southern India.Infectio.201923325325810.22354/in.v23i3.789
     [Google Scholar]
  14. ChouS.T. GibsonJ.B. Experimental cholangitis and cholelithiasis.Br. J. Exp. Pathol.1968496565573 4884386
     [Google Scholar]
  15. ChangK.K. ChangC.L. TaiF.T. WangC.H. LinR.C. Empiric antibiotic choices for community-acquired biliary tract infections.Adv. Digest Med.20141545910.1016/j.aidm.2013.09.002
     [Google Scholar]
  16. Al-ZuharriOA Isolation and identification of bacteria from patients with cholecystits and cholelithiasis undergoing cholecystectomy.Al-Kufa J Biol201131
     [Google Scholar]
  17. CapoorMR NairD Rajni Microflora of bile aspirates in patients with acute cholecystitis with or without cholelithiasis: a tropical experience.Braz. J. Infect. Dis.2008123222225 18839486
     [Google Scholar]
  18. MananF. KhanM.A. FarazA. KhanM. Frequency of common bacteria and their antibiotic sensitivity in patients with symptomatic cholelithiasis.J. Postgrad. Med. Inst.2014282
     [Google Scholar]
  19. van VelkinburghJ.C. GunnJ.S. PhoP-PhoQ-regulated loci are required for enhanced bile resistance in Salmonella spp.Infect. Immun.19996741614162210.1128/IAI.67.4.1614‑1622.1999 10084994
     [Google Scholar]
  20. ChemmanurA.T. Biliary Disease.Medscape2018
     [Google Scholar]
  21. LjunghÅ. WadströmT. The role of microorganisms in biliary tract disease.Curr. Gastroenterol. Rep.20024216717110.1007/s11894‑002‑0055‑6 11900683
     [Google Scholar]
  22. HofmannA.F. Bile acids: the good, the bad, and the ugly.Physiology (Bethesda)1999141242910.1152/physiologyonline.1999.14.1.24 11390813
     [Google Scholar]
  23. BegleyM. SleatorR.D. GahanC.G.M. HillC. Contribution of three bile-associated loci, bsh, pva, and btlB, to gastrointestinal persistence and bile tolerance of Listeria monocytogenes.Infect. Immun.200573289490410.1128/IAI.73.2.894‑904.2005 15664931
     [Google Scholar]
  24. MasedaE. MaggiG. Gomez-GilR. Prevalence of and risk factors for biliary carriage of bacteria showing worrisome and unexpected resistance traits.J. Clin. Microbiol.201351251852110.1128/JCM.02469‑12 23196362
     [Google Scholar]
  25. BajajA. ThakurA. MishraB. Multidrug resistant bacteria causing biliary tract infection: A tertiary care centre study from North India.Saudi J Pathol Microbiol201943245249
     [Google Scholar]
  26. AdamsD.B. BorowiczM.R. Taylor WoottonF.III CunninghamJ.T. Bile duct complications after laparoscopic cholecystectomy.Surg. Endosc.199372798310.1007/BF00704382 8456373
     [Google Scholar]
  27. GérardP. Metabolism of cholesterol and bile acids by the gut microbiota.Pathogens201331142410.3390/pathogens3010014 25437605
     [Google Scholar]
  28. BrestoffJ.R. ArtisD. Commensal bacteria at the interface of host metabolism and the immune system.Nat. Immunol.201314767668410.1038/ni.2640 23778795
     [Google Scholar]
  29. VerdierJ. LueddeT. SellgeG. Biliary mucosal barrier and microbiome.Viszeralmedizin2015313156161 26468308
     [Google Scholar]
  30. BarnesD. Gallbladder and biliary tract disease.Cleavel and Clinic201010.1016/B978‑1‑4160‑6643‑9.00074‑6
     [Google Scholar]
  31. FreemanM.L. Complications of endoscopic biliary sphincterotomy: a review.Endoscopy199729428829710.1055/s‑2007‑1004193 9255535
     [Google Scholar]
  32. CsendesA. FernandezM. UribeP. Bacteriology of the gallbladder bile in normal subjects.Am. J. Surg.1975129662963110.1016/0002‑9610(75)90334‑7 805546
     [Google Scholar]
  33. ShenoyS.M. ShenoyS. GopalS. TantryB.V. BaligaS. JainA. Clinicomicrobiological analysis of patients with cholangitis.Int. J. Med. Microbiol.2014322157160 24713902
     [Google Scholar]
  34. ShimadaK. NoroT. InamatsuT. UrayamaK. AdachiK. Bacteriology of acute obstructive suppurative cholangitis of the aged.J. Clin. Microbiol.198114552252610.1128/jcm.14.5.522‑526.1981 6273452
     [Google Scholar]
  35. MelzerM. TonerR. LaceyS. BettanyE. RaitG. Biliary tract infection and bacteraemia: presentation, structural abnormalities, causative organisms and clinical outcomes.Postgrad. Med. J.20078398677377610.1136/pgmj.2007.064683 18057178
     [Google Scholar]
  36. KayaM. BeştaşR. BacalanF. BacaksızF. ArslanE.G. KaplanM.A. Microbial profile and antibiotic sensitivity pattern in bile cultures from endoscopic retrograde cholangiography patients.World J. Gastroenterol.201218273585358910.3748/wjg.v18.i27.3585 22826624
     [Google Scholar]
  37. RerknimitrR. FogelE.L. KalayciC. EsberE. LehmanG.A. ShermanS. Microbiology of bile in patients with cholangitis or cholestasis with and without plastic biliary endoprosthesis.Gastrointest. Endosc.200256688588910.1016/S0016‑5107(02)70365‑9 12447303
     [Google Scholar]
  38. NeveR. BiswasS. DhirV. Bile cultures and sensitivity patterns in malignant obstructive jaundice.Indian J. Gastroenterol.20032211618 12617446
     [Google Scholar]
  39. KatyalA. BalaK. BansalA. ChaudharyU. Clinico-microbiological analysis of bactibilia isolates in patients of cholecystectomy.Int. J. Res. Med. Sci.2017594030403510.18203/2320‑6012.ijrms20173977
     [Google Scholar]
  40. BarveS. ChenS.Y. KirpichI. WatsonW.H. McclainC. Development, prevention, and treatment of alcohol-induced organ injury: the role of nutrition.Alcohol Res.2017382289302 28988580
     [Google Scholar]
  41. UdompapP. KimD. KimW.R. Current and future burden of chronic nonmalignant liver disease.Clin. Gastroenterol. Hepatol.201513122031204110.1016/j.cgh.2015.08.015 26291665
     [Google Scholar]
  42. Abdel-RahmanH.G. AbdelrazekH.M.A. ZeidanD.W. MohamedR.M. AbdelazimA.M. Lycopene: Hepatoprotective and Antioxidant Effects toward Bisphenol A‐Induced Toxicity in Female Wistar Rats.Oxid. Med. Cell. Longev.201820181516752410.1155/2018/5167524 30147835
     [Google Scholar]
  43. ZhuR.X. SetoW.K. LaiC.L. YuenM.F. Epidemiology of hepatocellular carcinoma in the Asia-Pacific region.Gut Liver201610333233910.5009/gnl15257 27114433
     [Google Scholar]
  44. DeyP. SahaM. SenA. Hepatotoxicity and the present herbal hepatoprotective scenario.Int. J. Green Pharm.20137426527310.4103/0973‑8258.122046
     [Google Scholar]
  45. SharmaC.K. SharmaM. SharmaV. Therapeutic potential of a medicinal plant Aegle marmelos (L.) corr.: an insight.J. Environ. Pathol. Toxicol. Oncol.201635111010.1615/JEnvironPatholToxicolOncol.2015014485 27279580
     [Google Scholar]
  46. SharmaM. YadavI. SharmaC.K. Histopathological evaluation of hepatoprotective activity of Aegle marmelos (l.) corr. against carbon tetrachloride induced toxicity.Ecol Environ and Conser201925313431346
     [Google Scholar]
  47. SinghR.K. SharmaM. SharmaC.K. Protective mechanism of Vitis vinifera L. Fruit (V. Vinifera) loaded polymeric nanoparticles on acute liver injury induced by acetaminophen toxicity.Int. J. Biol. Pharm. Allied Sci.2022111151955210
     [Google Scholar]
  48. PathakP. SharmaC.K. Biogenic metallic nanoparticles and their anticancer activities: Biotechnological perspectives.Res. J. Biotechnol.2021161117718510.25303/1611rjbt177185
     [Google Scholar]
  49. SharmaM. YadavI. SharmaC.K. Therapeutic efficacy of hepatoprotective activity of Aegle marmelos (L.) Corr. fruit against carbon tetrachloride induced damage in rats. Int. j.Agricult Stat Sci2019151175181
     [Google Scholar]
  50. SharmaM. YadavI. SharmaC.K. Applications of novel polymeric nanoparticles and natural plant products in drug delivery for various therapeutic purposes. Int. j.Agricult Stat Sci2018142529537
     [Google Scholar]
  51. SharmaC.K. SharmaM. SharmaV. Therapeutic potential of medicinal plants in the drug development against cancer and hepatic injury- An overview.Vegetos2018318792
     [Google Scholar]
  52. BruchezP. PittetA. MagistrettiP.J. Toxicity of chemicals: a case study of carbon tetrachloride.Toxicol. Lett.19981001-3387395
     [Google Scholar]
  53. JaeschkeH. McGillM.R. RamachandranA. Oxidant stress, mitochondria, and cell death mechanisms in drug-induced liver injury: Lessons learned from acetaminophen hepatotoxicity.Drug Metab. Rev.20124418810610.3109/03602532.2011.602688 22229890
     [Google Scholar]
  54. FattovichG. StroffoliniT. ZagniI. DonatoF. Hepatocellular carcinoma in cirrhosis: Incidence and risk factors.Gastroenterology20041275Suppl. 1S35S5010.1053/j.gastro.2004.09.014 15508101
     [Google Scholar]
  55. CoeM. ShiranM. SpectorE. Xenobiotics and liver injury.Toxicol. Sci.2002652166176 11812920
     [Google Scholar]
  56. LuY. CederbaumA.I. AutophagyC. Research: oxidative stress and antioxidant defense mechanisms in the liver.Oxid. Med. Cell. Longev.20192019115
     [Google Scholar]
  57. FriedmanS.L. Mechanisms of hepatic fibrogenesis.Gastroenterology200813461655166910.1053/j.gastro.2008.03.003 18471545
     [Google Scholar]
  58. KunjiappanS. BhattacharjeeC. ChowdhuryR. Hepatoprotective and antioxidant effects ofAzolla microphylla based gold nanoparticles against acetaminophen induced toxicity in a fresh water common carp fish (Cyprinus caprio).Nanomed. J.20152288110
     [Google Scholar]
  59. YeC. DongC. LinY. ShiH. ZhouW. Interplay between the Human Microbiome and Biliary Tract Cancer: Implications for Pathogenesis and Therapy.Microorganisms20231110259810.3390/microorganisms11102598 37894256
     [Google Scholar]
  60. WangK. WangS. QinX. The causal relationship between gut microbiota and biliary tract cancer: comprehensive bidirectional Mendelian randomization analysis.Front. Cell. Infect. Microbiol.202414130874210.3389/fcimb.2024.1308742 38558852
     [Google Scholar]
  61. WheatleyR.C. KilgourE. JacobsT. Potential influence of the microbiome environment in patients with biliary tract cancer and implications for therapy.Br. J. Cancer2022126569370510.1038/s41416‑021‑01583‑8 34663949
     [Google Scholar]
  62. BridgewaterJ. GalleP.R. KhanS.A. Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma.J. Hepatol.20146061268128910.1016/j.jhep.2014.01.021 24681130
     [Google Scholar]
  63. BrindleyP.J. BachiniM. Cholangiocarcinoma.Nat. Rev. Dis. Primers2021765
     [Google Scholar]
  64. CiomborK.K. GoffL.W. Advances in the management of biliary tract cancers.Clin. Adv. Hematol. Oncol.20131112834 23416860
     [Google Scholar]
  65. NakamuraH. AraiY. TotokiY. Genomic spectra of biliary tract cancer.Nat. Genet.20154791003101010.1038/ng.3375 26258846
     [Google Scholar]
  66. LiY. SongY. LiuS. The new insight of treatment in Cholangiocarcinoma.J. Cancer202213245046410.7150/jca.68264 35069894
     [Google Scholar]
  67. KokaK. VermaA. DwarakanathB.S. PapineniR.V.L. Technological Advancements in External Beam Radiation Therapy (EBRT): An Indispensable Tool for Cancer Treatment.Cancer Manag. Res.2022141421142910.2147/CMAR.S351744 35431581
     [Google Scholar]
  68. PrimroseJ.N. FoxR.P. PalmerD.H. MalikH.Z. PrasadR. MirzaD. Lancet Oncol.201415994395310.1016/S1470‑2045(14)70314‑6 25035291
     [Google Scholar]
  69. Abou-AlfaG.K. SahaiV. HollebecqueA. VaccaroG. MelisiD. Al-RajabiR. Lancet Oncol.2021223427437 33676604
     [Google Scholar]
  70. ZhuA.X. FinnR.S. EdelineJ. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial.Lancet Oncol.201819794095210.1016/S1470‑2045(18)30351‑6 29875066
     [Google Scholar]
  71. DohertyM.K. KnoxJ.J. Al-RajabiR. Future directions in advanced biliary tract cancer: Immunotherapy and targeted therapies.J. Clin. Oncol.2021391415981605 33705202
     [Google Scholar]
  72. JavleM. LoweryM. ShroffR.T. WeissK.H. SpringfeldC. BoradM.J. J. Clin. Oncol.20203828271279 31751163
     [Google Scholar]
  73. ValleJ. WasanH. PalmerD.H. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer.N. Engl. J. Med.2010362141273128110.1056/NEJMoa0908721 20375404
     [Google Scholar]
  74. GopalP. RobertM.E. ZhangX. Cholangiocarcinoma: Pathologic and Molecular Classification in the Era of Precision Medicine.Arch. Pathol. Lab. Med.2024148335937010.5858/arpa.2022‑0537‑RA 37327187
     [Google Scholar]
  75. ChangB.K. TimmermanR.D. Stereotactic body radiation therapy: a comprehensive review.Am. J. Clin. Oncol.200730663764410.1097/COC.0b013e3180ca7cb1 18091059
     [Google Scholar]
  76. TaylorA. PowellM.E. Intensity-modulated radiotherapy - what is it?Cancer Imaging200442687310.1102/1470‑7330.2004.0003 18250011
     [Google Scholar]
/content/journals/iddt/10.2174/0118715265302000240913092037
Loading
Significant Microbial Pathogenesis Perspective of Biliary Diseases
Infect. Disord. Drug Targets 25, E18715265302000 (2025); https://doi.org/10.2174/0118715265302000240913092037
/content/journals/iddt/10.2174/0118715265302000240913092037
/content/journals/iddt/10.2174/0118715265302000240913092037
Loading

Data & Media loading...


  • Article Type:     Review Article
Keyword(s): bile; Biliary diseases; gall bladder; liver; symptoms; treatments

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test